UZH-Logo

Maintenance Infos

Paclitaxel: cost–effectiveness in ovarian cancer


Dedes, K J; Bramkamp, M; Szucs, T D (2005). Paclitaxel: cost–effectiveness in ovarian cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 5(3):235-243.

Abstract

Ovarian cancer accounts for a significant burden of healthcare costs worldwide. Therapy of this disease consists of a combined surgical and chemotherapeutic approach. Remarkable advances in chemotherapy have been made with the introduction of new agents such as paclitaxel. Based on positive clinical data from randomized trials, numerous cost studies have been undertaken to analyze the cost–effectiveness of paclitaxel. Reviewing all the available cost studies, the authors conclude that paclitaxel plus cisplatin treatment is cost effective. Paclitaxel demonstrated survival and utility gains in combination with cisplatin as first-line treatment in patients with Stage II–IV ovarian cancer compared with cyclophosphamide and cisplatin. Incremental costs of US$6600–22,000 per life year gained are within an accepted range for new treatments.

Ovarian cancer accounts for a significant burden of healthcare costs worldwide. Therapy of this disease consists of a combined surgical and chemotherapeutic approach. Remarkable advances in chemotherapy have been made with the introduction of new agents such as paclitaxel. Based on positive clinical data from randomized trials, numerous cost studies have been undertaken to analyze the cost–effectiveness of paclitaxel. Reviewing all the available cost studies, the authors conclude that paclitaxel plus cisplatin treatment is cost effective. Paclitaxel demonstrated survival and utility gains in combination with cisplatin as first-line treatment in patients with Stage II–IV ovarian cancer compared with cyclophosphamide and cisplatin. Incremental costs of US$6600–22,000 per life year gained are within an accepted range for new treatments.

Citations

Altmetrics

Downloads

1 download since deposited on 09 Jun 2009
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2005
Deposited On:09 Jun 2009 07:33
Last Modified:05 Apr 2016 13:15
Publisher:Expert Reviews Ltd
ISSN:1473-7167
Publisher DOI:https://doi.org/10.1586/14737167.5.3.235
Permanent URL: https://doi.org/10.5167/uzh-19002

Download

[img]
Filetype: PDF - Registered users only
Size: 9MB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations